Endo was struggling—hard—when CEO Rajiv de Silva departed last September, turning the reins over to current chief Paul Campanelli. But that didn’t stop de Silva from tallying more than $19 million in 2016 pay.

De Silva scored $19.18 million for helming Endo for less than 10 months last year, a sum that nearly doubled the $10.91 million he pocketed the year before. On top of a base salary of $840,337, Endo handed him more than $10 million in share awards and $2.5 million in options.

De Silva also nabbed more than $5.6 million in other compensation—most of which came in the form of $5.2 million in severance pay. Also included: Endo forked over $94,932 rather than give de Silva 30 days' notice that he'd be terminated, and paid $250,000 for his accrued vacation.

Virtual Roundtable ESMO Post Show: Highlights from the Virtual Conference Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today. Save Your Spot

RELATED: It's out with the old CEO, in with the new as Endo's Campanelli takes De Silva's seat

De Silva’s golden parachute isn’t as big as it might have been had Endo’s shares performed better, though. His options are valueless today, but theoretically could regain value if Endo’s shares take an upturn.

Lately, however, investors haven’t had a whole lot to be excited about. In late February, the company recorded a $3.5 billion writedown, thanks to its suffering generics unit; that event followed three layoffs announcements and a slew of executive exits, including De Silva’s.

RELATED: Struggling Endo takes $3.5B body blow as generics pricing heads south

RBC Capital Markets analyst Randall Stanicky is upbeat about the company’s future, however; as he wrote in a note to clients last month, “there is some potential for surprise going forward.

“Management has taken several steps to refocus the business and we walk away from our meeting with the feeling that focus on execution is high,” he said.